Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

34.45USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$34.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,289,319
52-wk High
$42.49
52-wk Low
$19.32

Select another date:

Tue, Feb 28 2017

BRIEF-Acadia Pharmaceuticals Q4 loss per share $0.65

* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016

Acadia says Alzheimer's psychosis drug clears mid-stage study

Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent.

BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin

* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage:

BRIEF-UK's CMA says accepted proposals in Acadia's Priory Group deal

Nov 10 UK's Competition and Markets Authority (CMA):

BRIEF-Acadia Pharmaceuticals initiates phase III trial of pimavanserin for adjunctive treatment in patients with Schizophrenia

* Acadia Pharmaceuticals initiates phase iii trial of pimavanserin for adjunctive treatment in patients with Schizophrenia Source text for Eikon: Further company coverage:

BRIEF-Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation

* Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation Source text for Eikon: Further company coverage:

GM to add 650 jobs at Spring Hill factory to meet SUV demand

General Motors said it would add a third shift and 650 jobs at its factory in Spring Hill, Tennessee to meet higher demand for its recently launched Cadillac XT5 and GMC Acadia crossover SUVs.

Select another date:

More From Around the Web